AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023-Reference-Cited by-同舟云学术

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023

Published:2023 Issue:4 Volume:18 Page:306-315
ISSN:1661-3791
Container-title:Breast Care
language:en
Short-container-title:Breast Care

Author:

Thill Marc^ORCID,Kolberg-Liedtke Cornelia,Albert Ute-Susann,Banys-Paluchowski Maggie,Bauerfeind Ingo,Blohmer Jens-Uwe^ORCID,Budach Wilfried,Dall Peter^ORCID,Ditsch Nina,Fallenberg Eva Maria^ORCID,Fasching Peter A.,Fehm Tanja,Friedrich Michael,Gerber Bernd,Gluz Oleg,Harbeck Nadia,Hartkopf Andreas D.,Heil Joerg,Huober Jens,Jackisch Christian,Kreipe Hans H.,Krug David,Kühn Thorsten,Kümmel Sherko,Loibl Sibylle,Lüftner Diana,Lux Michael Patrick,Maass Nicolai,Mundhenke Christoph,Reimer Toralf,Rhiem Kerstin,Rody Achim,Schmidt Marcus,Schneeweiss Andreas,Schütz Florian^ORCID,Sinn Hans Peter^ORCID,Solbach Christine^ORCID,Solomayer Erich-Franz^ORCID,Stickeler Elmar,Thomssen Christoph,Untch Michael^ORCID,Witzel Isabell,Wöckel Achim,Wuerstlein Rachel,Müller Volkmar,Janni Wolfgang,Park-Simon Tjoung-Won^ORCID

Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2023 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).

Publisher

S. Karger AG

Subject

Oncology,Surgery

Link

https://karger.com/brc/article-pdf/18/4/305/3989415/000531579.pdf

Reference38 articles.

1. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

3. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

4. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

5. NTRK fusion-positive cancers and TRK inhibitor therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management;Cancers;2023-11-17

2. Endocrine Therapy: From Ovarian Ablation to Individualized Therapy and Signal Inhibition;Breast Care;2023